ALK gene alterations such as gene fusions, mutations and amplification have also been described in multiple solid tumors apart from NSCLC including, but not limited to, inflammatory myelofibrotic tumor (IMT), neuroblastoma, esophageal carcinoma, renal medullary carcinoma, breast carcinoma, colorectal carcinoma, serous ovarian carcinoma, and thyroid carcinoma. Here, ALK is linked to inflammatory myofibroblastic tumor.